These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 37944561)
1. Prevalence of COVID-19 and Psychotropic Drug Treatment in Psychiatric In-patients in Germany in 2020: Results from a Nationwide Pilot Survey. Mueller JK; Ahrens KF; Bauer M; Baune BT; Borgwardt S; Deckert J; Domschke K; Ellwanger R; Fallgatter A; Frodl T; Gallinat J; Gottschalk R; Grabe HJ; Hasan A; Herpertz SC; Hurlemann R; Jessen F; Kambeitz J; Kircher T; Kornhuber J; Lieb K; Meyer-Lindenberg A; Rupprecht R; Scherbaum N; Schlang C; Schneider A; Schomerus G; Thoma A; Unterecker S; Walter M; Walter H; Reif A; Reif-Leonhard C Pharmacopsychiatry; 2023 Nov; 56(6):227-238. PubMed ID: 37944561 [TBL] [Abstract][Full Text] [Related]
2. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic]. Javelot H; Llorca PM; Drapier D; Fakra E; Hingray C; Meyer G; Dizet S; Egron A; Straczek C; Roser M; Masson M; Gaillard R; Fossati P; Haffen E Encephale; 2020 Jun; 46(3S):S14-S34. PubMed ID: 32376004 [TBL] [Abstract][Full Text] [Related]
3. Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System. Nemani K; Williams SZ; Olfson M; Leckman-Westin E; Finnerty M; Kammer J; Smith TE; Silverman DJ; Lindenmayer JP; Capichioni G; Clelland J; Goff DC JAMA Netw Open; 2022 May; 5(5):e2210743. PubMed ID: 35522282 [TBL] [Abstract][Full Text] [Related]
4. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
6. Association of SARS-CoV-2 Infection With Psychological Distress, Psychotropic Prescribing, Fatigue, and Sleep Problems Among UK Primary Care Patients. Abel KM; Carr MJ; Ashcroft DM; Chalder T; Chew-Graham CA; Hope H; Kapur N; McManus S; Steeg S; Webb RT; Pierce M JAMA Netw Open; 2021 Nov; 4(11):e2134803. PubMed ID: 34783824 [TBL] [Abstract][Full Text] [Related]
7. Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis. Fico G; Isayeva U; De Prisco M; Oliva V; Solè B; Montejo L; Grande I; Arbelo N; Gomez-Ramiro M; Pintor L; Carpiniello B; Manchia M; Vieta E; Murru A Eur Neuropsychopharmacol; 2023 Jan; 66():30-44. PubMed ID: 36399837 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 patients managed in psychiatric inpatient settings due to first-episode mental disorders in Wuhan, China: clinical characteristics, treatments, outcomes, and our experiences. Xie Q; Fan F; Fan XP; Wang XJ; Chen MJ; Zhong BL; Chiu HF Transl Psychiatry; 2020 Oct; 10(1):337. PubMed ID: 33009366 [TBL] [Abstract][Full Text] [Related]
9. Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study. Hoertel N; Sánchez-Rico M; Gulbins E; Kornhuber J; Carpinteiro A; Abellán M; de la Muela P; Vernet R; Beeker N; Neuraz A; Delcuze A; Alvarado JM; Cougoule C; Meneton P; Limosin F; Transl Psychiatry; 2022 Mar; 12(1):90. PubMed ID: 35241663 [TBL] [Abstract][Full Text] [Related]
10. Exposure to psychotropic medications and COVID-19 course after hospital admission: Results from a prospective cohort study. D'Andrea G; Pascale R; Vatamanu O; Giacomini ME; Caroccia N; Giannella M; Carloni AL; Cesa F; Mordenti O; Muratori R; Tarricone I; Viale P J Psychosom Res; 2023 Apr; 167():111199. PubMed ID: 36827888 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461 [TBL] [Abstract][Full Text] [Related]
12. Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances. Javelot H; Petrignet J; Addiego F; Briet J; Solis M; El-Hage W; Hingray C; Weiner L Med Hypotheses; 2020 Nov; 144():110025. PubMed ID: 33254478 [TBL] [Abstract][Full Text] [Related]
13. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197 [TBL] [Abstract][Full Text] [Related]
14. Letter to the Editor: THE IMPACT OF THE COVID-19 PANDEMIC ON SCHIZOPHRENIA PATIENTS. Hoşgelen EI; Alptekin K Turk Psikiyatri Derg; 2021; 32(3):219-221. PubMed ID: 34637131 [TBL] [Abstract][Full Text] [Related]
15. Letter to the Editor: THE IMPACT OF THE COVID-19 PANDEMIC ON SCHIZOPHRENIA PATIENTS. Hoşgelen EI; Alptekin K Turk Psikiyatri Derg; 2021; 32(3):219-221. PubMed ID: 34750798 [TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Felten R; Scherlinger M; Guffroy A; Poindron V; Meyer A; Giannini M; Korganow AS; Sordet C; Chatelus E; Javier RM; Meyer A; Pijnenburg L; Kleinmann JF; Gottenberg JE; Sibilia J; Martin T; Arnaud L Arthritis Res Ther; 2021 Jul; 23(1):188. PubMed ID: 34256812 [TBL] [Abstract][Full Text] [Related]
17. Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population. Wang Y; Su B; Xie J; Garcia-Rizo C; Prieto-Alhambra D Nat Hum Behav; 2024 Jun; 8(6):1076-1087. PubMed ID: 38514769 [TBL] [Abstract][Full Text] [Related]
18. Prevalence, management, and outcomes of SARS-CoV-2 infections in older people and those with dementia in mental health wards in London, UK: a retrospective observational study. Livingston G; Rostamipour H; Gallagher P; Kalafatis C; Shastri A; Huzzey L; Liu K; Sommerlad A; Marston L Lancet Psychiatry; 2020 Dec; 7(12):1054-1063. PubMed ID: 33031760 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 and risk of psychiatric hospital admission and use of psychopharmaceuticals: A nationwide registry study of 4,585,083 adult Danish citizens. Rømer V; Sivapalan P; Eklöf J; Nielsen SD; Harboe ZB; Biering-Sørensen T; Itenov T; Jensen JS Eur Psychiatry; 2023 Jun; 66(1):e50. PubMed ID: 37282564 [TBL] [Abstract][Full Text] [Related]
20. [Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic]. Andrade G; Simões do Couto F; Câmara-Pestana L Acta Med Port; 2020 Oct; 33(10):693-702. PubMed ID: 32705981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]